Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-((1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
2. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
3. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-, Methanesulfonate (1:2)
4. D-824
5. D-824 Dimesylate
6. D824
7. Gzd-824
8. Gzd-824 Dimesylate
9. Gzd824
10. Hqp-1351
11. Hqp-1351 Dimesylate
12. Hqp1351
13. Hqp1351 Dimesylate
14. Olverembatinib
15. Olverembatinib Dimesylate
1. 1257628-77-5
2. Gzd824
3. Olverembatinib
4. Gzd-824
5. Hqp1351
6. Olverembatinib [usan]
7. Hqp-1351
8. Kv1m7q3cbp
9. 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
10. Chembl2316582
11. D-824
12. Gzd 824
13. Benzamide, 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-
14. Olverembatinib Dimesylate
15. Hqp1351 Dimesylate
16. Hqp-1351 Dimesylate
17. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
18. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-
19. 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
20. 4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1h-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide
21. Hqp1351 Free Base
22. Hqp-1351 Free Base
23. Unii-kv1m7q3cbp
24. Olverembatinib [inn]
25. Schembl3424528
26. Olverembatinib [who-dd]
27. Gtpl10630
28. Ex-a829
29. Bcp07502
30. Bdbm50425780
31. Who 11221
32. Zinc95594040
33. Akos026750647
34. Cs-1444
35. Sb16617
36. Compound 10a [pmid: 23301703]
37. Ncgc00351607-06
38. Ac-35436
39. As-75170
40. Hy-15666
41. Ft-0700150
42. A16264
43. C72036
44. A899056
45. J-690110
| Molecular Weight | 532.6 g/mol |
|---|---|
| Molecular Formula | C29H27F3N6O |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 532.21984399 g/mol |
| Monoisotopic Mass | 532.21984399 g/mol |
| Topological Polar Surface Area | 77.2 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 910 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
HQP1351 (olverembatinib) is a 3rd-gen BCR-ABL inhibitor, being developed for newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2025
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Olverembatinib Gets Breakthrough Tag for Ph+ Acute Lymphoblastic Leukemia
Details : HQP1351 (olverembatinib) is a 3rd-gen BCR-ABL inhibitor, being developed for newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2025
Details:
HQP1351 (olverembatinib) is a novel, potent, & orally administered third-generation tyrosine kinase inhibitor. It is being evaluated for the treatment of SDH-deficient gastrointestinal stromal tumor.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China NMPA Approves Ascentage's Phase III Study of Olverembatinib for SDH-deficient GIST
Details : HQP1351 (olverembatinib) is a novel, potent, & orally administered third-generation tyrosine kinase inhibitor. It is being evaluated for the treatment of SDH-deficient gastrointestinal stromal tumor.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Details:
HQP1351 (olverembatinib), novel, orally administered 3G BCR-ABL1 inhibitor got CDE approval for its pivotal registrational Phase III study evaluating its efficacy in patients with SDH-deficient GIST.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China CDE Approves Olverembatinib Phase III Study for SDH-Deficient GIST
Details : HQP1351 (olverembatinib), novel, orally administered 3G BCR-ABL1 inhibitor got CDE approval for its pivotal registrational Phase III study evaluating its efficacy in patients with SDH-deficient GIST.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2024
Details:
This agreement would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib (BCR-ABL tyrosine kinase inhibitor) in all territories outside of China.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Takeda Pharmaceutical
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 14, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : $1,300.0 million
Deal Type : Licensing Agreement
Ascentage Signs Agreement with Takeda for Global License of Olverembatinib, a BCR-ABL TKI
Details : This agreement would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib (BCR-ABL tyrosine kinase inhibitor) in all territories outside of China.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 14, 2024
Details:
Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for (HQP1351) olverembatinib for Chronic Myeloid Leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Takeda Pharmaceutical
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 07, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : $1,300.0 million
Deal Type : Agreement
Ascentage Pharma Received US$100 Million Option Payment from Takeda
Details : Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for (HQP1351) olverembatinib for Chronic Myeloid Leukemia.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 07, 2024
Details:
Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib) for Chronic Myeloid Leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Takeda Pharmaceutical
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 07, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : $1,300.0 million
Deal Type : Agreement
Ascentage Pharma Received US$100 Million Option Payment from Takeda
Details : Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib) for Chronic Myeloid Leukemia.
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 07, 2024
Details:
HQP1351 (olverembatinib) is a third-generation BCR-ABL inhibitor. It is being developed for the treatment of previously treated adult patients with chronic-phase chronic myeloid leukemia (CML-CP).
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2024
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
Details : HQP1351 (olverembatinib) is a third-generation BCR-ABL inhibitor. It is being developed for the treatment of previously treated adult patients with chronic-phase chronic myeloid leukemia (CML-CP).
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2024
Details:
HQP1351 (olverembatinib), a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor, received breakthrough therapy designation by NMPA for olverembatinib for the treatment of patients with naïve philadelphia chromosome-positive acute lymphoblastic leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2023
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Pa...
Details : HQP1351 (olverembatinib), a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor, received breakthrough therapy designation by NMPA for olverembatinib for the treatment of patients with naïve philadelphia chromosome-positive acute lymphoblas...
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2023
Details:
HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor received Breakthrough Therapy Designation (BTD) for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who had received first-line treatment.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Innovent Biologics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2023
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor received Breakthrough Therapy Designation (BTD) for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who had received first-line tr...
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Details:
HQP1351 (olverembatinib), a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor, received breakthrough therapy designation by NMPA for olverembatinib for the treatment of patients with naïve philadelphia chromosome-positive acute lymphoblastic leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Brand Name: HQP1351
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Shenzhen Second People's Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2023
Lead Product(s) : Olverembatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Shenzhen Second People's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HQP1351 (olverembatinib), a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor, received breakthrough therapy designation by NMPA for olverembatinib for the treatment of patients with naïve philadelphia chromosome-positive acute lymphoblas...
Product Name : HQP1351
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
13
PharmaCompass offers a list of Olverembatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olverembatinib manufacturer or Olverembatinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olverembatinib manufacturer or Olverembatinib supplier.
PharmaCompass also assists you with knowing the Olverembatinib API Price utilized in the formulation of products. Olverembatinib API Price is not always fixed or binding as the Olverembatinib Price is obtained through a variety of data sources. The Olverembatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Olverembatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olverembatinib, including repackagers and relabelers. The FDA regulates Olverembatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olverembatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Olverembatinib supplier is an individual or a company that provides Olverembatinib active pharmaceutical ingredient (API) or Olverembatinib finished formulations upon request. The Olverembatinib suppliers may include Olverembatinib API manufacturers, exporters, distributors and traders.
Olverembatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olverembatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olverembatinib GMP manufacturer or Olverembatinib GMP API supplier for your needs.
A Olverembatinib CoA (Certificate of Analysis) is a formal document that attests to Olverembatinib's compliance with Olverembatinib specifications and serves as a tool for batch-level quality control.
Olverembatinib CoA mostly includes findings from lab analyses of a specific batch. For each Olverembatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olverembatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olverembatinib EP), Olverembatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olverembatinib USP).
